Wuhan Ebitda from 2010 to 2024

300871 Stock   11.40  0.01  0.09%   
Wuhan Hvsen's EBITDA is increasing over the years with slightly volatile fluctuation. EBITDA is expected to dwindle to about 152.5 M. From 2010 to 2024 Wuhan Hvsen EBITDA quarterly data regression line had arithmetic mean of  129,938,005 and r-squared of  0.35. View All Fundamentals
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
158.3 M
Current Value
152.5 M
Quarterly Volatility
29.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Wuhan Hvsen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Wuhan Hvsen's main balance sheet or income statement drivers, such as Interest Expense of 29.6 M, Other Operating Expenses of 5.6 M or Net Income Applicable To Common Shares of 96.4 M, as well as many indicators such as . Wuhan financial statements analysis is a perfect complement when working with Wuhan Hvsen Valuation or Volatility modules.
  
This module can also supplement various Wuhan Hvsen Technical models . Check out the analysis of Wuhan Hvsen Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Wuhan Stock

Wuhan Hvsen financial ratios help investors to determine whether Wuhan Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Wuhan with respect to the benefits of owning Wuhan Hvsen security.